A t-shirt that monitors a patient’s vitals after urological surgery for cancer could help people return from hospital sooner to recover at home. The device, worn for around two weeks under clothes for three-hour windows each day, enabled patients to feel safer and more reassured than a control group in a pilot study of 70 individuals.

Men who consistently avoid prostate cancer screening appointments face a disproportionately higher risk of dying from the disease, finds research identifying a new high-risk group.

Researchers at the Institute for Systems Biology (ISB) in Seattle have uncovered a stealth survival strategy that melanoma cells use to evade targeted therapy, offering a promising new approach to improving treatment outcomes.

In addition to exporting materials out of the nucleus, the protein, called Exportin-1 (also called Xpo1 or Crm1), seems to play a role in promoting gene transcription, the process that creates RNA replicas of strands of DNA to express genes.

About The Study: In this cohort study of patients with ovarian cancer, American Indian and Black patients were 23% less likely to have an elevated cancer antigen (CA)-125 level at diagnosis. Current CA-125 thresholds may miss racially and ethnically diverse patients with ovarian cancer. International guidelines use CA-125 thresholds to recommend which patients with pelvic masses should undergo evaluation by gynecologic oncologists for ovarian cancer. However, CA-125 thresholds were developed from white populations. Work is needed to develop inclusive CA-125 thresholds and diagnostic guidelines and not compound disparities in ovarian cancer diagnosis and treatment.

A  team of researchers from Cleveland Clinic share insights from an early set of 19,000 patients to receive immune checkpoint inhibitor treatments for colorectal cancer in the US.  

The report comes from the laboratory of Stephanie Schmit, PhD, MPH, and was published in JAMA Network Open. It serves as an opportunity to better understand how immune checkpoint inhibitor treatments, including PD-1 and PD-L1 inhibitors, work in a larger population that reflects real-world settings. Dr. Schmit collaborated with a team of researchers that included Moffitt Cancer Center.